San Diego, CA -- Jan. 16, 2003 -- TargeGen, Inc., a biotechnology company focusing on cardiovascular diseases and cancer, today announced the appointment of David E. McClure as Vice President of Regulatory Affairs & Drug Development.

Dr. McClure has over 27 yrs of industry experience in the regulatory and development fields with companies including Merck, McNeil Pharmaceuticals (J&J), ICI, Molecular Biosystems and Sibia Neurosciences. Most recently, Dr. McClure served as Vice President, Drug Development at Signal Research Division of Celgene.

"We are extremely pleased to be able to add someone of Dr. McClure's experience in regulatory affairs and drug development to our senior management team" said Peter G. Ulrich, President and CEO of TargeGen. "We are rapidly advancing our first product candidates for cardiovascular disease and cancer into human clinical trials and David's depth of experience is expected to significantly increase the efficiency of that process."

Dr. McClure earned a Ph.D. in Organic Chemistry from Stanford University and conducted post doctoral research at Columbia University before moving into industry. He is an author on 22 scientific publications and is named as an inventor on 20 issued or pending patents.

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company established in July 2001. TargeGen is developing novel therapeutics to treat cancer and ischemic disease (stroke, heart attack) by regulating the processes associated with new blood vessel formation (angiogenesis) and vascular permeability (VP).

In March 2002, TargeGen executed a comprehensive licensing agreement with Merck KGaA (Darmstadt, Germany). This agreement provided TargeGen with access to a portfolio comprised of more than 100 pending and issued patents in the field of vascular biology. Also in March 2002, TargeGen completed a $10M Series "A" financing. The company's first funding round was led by Forward Ventures (San Diego), with significant participation by Enterprise Partners (La Jolla) and other investors.

For additional information, contact:
Peter G. Ulrich, President & CEO
TargeGen, Inc.
9393 Towne Centre Drive
Suite 120
San Diego, CA 92121
Tel 858-678-0760
Fax 858-678-0762
ulrich@targegen.com
http://www.targegen.com